Last reviewed · How we verify
F901318 Dose level A oral
At a glance
| Generic name | F901318 Dose level A oral |
|---|---|
| Also known as | antifungal agent |
| Sponsor | F2G Biotech GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options (PHASE2)
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Renal Impairment (PHASE1)
- A Phase I Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment (PHASE1)
- Drug-drug Interaction (DDI) Study to Assess Effect of Itraconazole and Rifampicin Upon Olorofim (PHASE1)
- Absorption, Metabolism and Excretion of 14C-olorofim in Man (PHASE1)
- Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects (PHASE1)
- Single Ascending Oral Dose Study of F901318 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F901318 Dose level A oral CI brief — competitive landscape report
- F901318 Dose level A oral updates RSS · CI watch RSS
- F2G Biotech GmbH portfolio CI